Our Pricing

Weight Loss Clinic Salisbury: Expert Prescription Treatment & Support

Published: 30 September 2026

Finding a reliable weight loss clinic Salisbury residents can trust for prescription medications requires a UK-registered pharmacy with qualified clinical oversight. Cured Pharmacy provides comprehensive weight loss services including Mounjaro, Wegovy, and Saxenda, all dispensed following online clinical assessment by our UK-registered prescribers. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every patient receives genuine UK-licensed medications with full regulatory compliance.

What Services Does a Weight Loss Clinic Salisbury Offer?

A professional weight loss clinic Salisbury service provides access to prescription-only medications including GLP-1 receptor agonists like tirzepatide (Mounjaro) and semaglutide (Wegovy, Saxenda). These treatments work by mimicking natural hormones that regulate appetite and blood sugar, helping patients achieve clinically significant weight reduction when combined with lifestyle modifications [1]. At Cured Pharmacy, all prescription weight loss medications require completion of a clinical assessment by a UK-registered prescriber to ensure suitability and safety.

Our weight loss clinic Salisbury service includes free online consultation completed in under three minutes, transparent upfront pricing from £124.99 for Mounjaro, and discreet home delivery across the UK. Clinical trials demonstrate that tirzepatide can produce average weight loss of 15-22% of body weight over 72 weeks, whilst semaglutide typically achieves 10-15% weight reduction [2]. Every treatment plan is individualised based on medical history, current medications, and weight loss goals, with ongoing support from our UK-registered clinical team.

Weight Loss Clinic Salisbury: Available Prescription Treatments

Patients accessing our weight loss clinic Salisbury service can choose from several evidence-based prescription options. Mounjaro (tirzepatide) represents the most effective treatment currently available, acting on both GIP and GLP-1 receptors to provide superior appetite control and metabolic benefits [3]. The SURPASS-2 trial demonstrated average weight loss of 12.4kg with the 15mg maintenance dose over 40 weeks, significantly outperforming semaglutide in head-to-head comparisons.

Wegovy (semaglutide injection) offers a well-established alternative with extensive clinical data supporting its efficacy and safety profile. For patients preferring oral medications, Wegovy tablets provide equivalent active ingredient in pill form, whilst Saxenda (liraglutide) requires daily injection but suits certain clinical scenarios. Orlistat-based treatments including Xenical, Alli, and Orlos work through a different mechanism by blocking dietary fat absorption, making them suitable for patients who cannot tolerate GLP-1 medications [4].

GLP-1 Receptor Agonists vs Fat Absorption Inhibitors

The weight loss clinic Salisbury treatments fall into two main categories with distinct mechanisms. GLP-1 receptor agonists (Mounjaro, Wegovy, Saxenda) reduce appetite centrally through hypothalamic pathways and slow gastric emptying, producing substantial weight loss averaging 10-22% depending on the specific medication. These require subcutaneous injection weekly or daily, though oral semaglutide now provides a non-injection option. Orlistat-based treatments work peripherally by inhibiting pancreatic lipase, preventing absorption of approximately 30% of dietary fat. Whilst producing more modest weight loss of 5-10%, orlistat suits patients with contraindications to GLP-1 therapies or those preferring a non-systemic mechanism.

How to Access Weight Loss Clinic Salisbury Services Online

Accessing our weight loss clinic Salisbury service begins with completing a confidential online clinical assessment covering medical history, current medications, cardiovascular risk factors, and weight loss goals. This assessment is reviewed by a UK-registered prescriber who determines suitability for prescription weight loss medication based on MHRA and NICE guidelines. Patients typically qualify with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [5].

Once approved, medications are dispensed from our GPhC-registered pharmacy (9012511) and delivered discreetly to any UK address including Salisbury and surrounding areas. The weight loss clinic Salisbury pricing structure is transparent with costs displayed before consultation: Mounjaro from £124.99, Wegovy from £124.99, and Saxenda from £124.99. New patients receive £20 off their first order using code Weightlossnew, reducing initial costs to £124.99 for Mounjaro. All medications are genuine UK-licensed products sourced through regulated pharmaceutical supply chains.

Clinical Assessment Requirements

The weight loss clinic Salisbury clinical assessment ensures patient safety by screening for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Prescribers evaluate concurrent medications for potential interactions, particularly with insulin or sulfonylureas which may require dose adjustment to prevent hypoglycaemia. Pregnancy, breastfeeding, and plans to conceive within the treatment period represent absolute contraindications to GLP-1 therapy. Our clinical team provides detailed guidance on dose escalation schedules, injection technique, and management of common side effects to optimise treatment outcomes.

Weight Loss Clinic Salisbury: Expected Results and Timelines

Patients using our weight loss clinic Salisbury prescription treatments typically observe initial weight loss within 4-8 weeks of starting therapy, with maximum effects achieved after 16-24 weeks at maintenance dose [6]. Tirzepatide (Mounjaro) produces the most substantial results, with clinical trial data showing average weight reduction of 15-22% over 72 weeks depending on final dose (10mg or 15mg). Semaglutide (Wegovy) achieves average weight loss of 10-15% over similar timeframes, whilst liraglutide (Saxenda) typically produces 5-10% reduction.

The weight loss clinic Salisbury approach emphasises realistic expectations and sustainable lifestyle changes alongside medication. GLP-1 therapies work by reducing appetite and increasing satiety, making it easier to maintain a calorie deficit, but they are not a substitute for healthy eating patterns and regular physical activity. Most patients experience gradual, steady weight loss rather than rapid drops, which supports better maintenance of results. Our clinical team recommends regular weight monitoring, dietary adjustments, and increased physical activity to maximise treatment effectiveness and develop long-term healthy behaviours.

Safety Profile of Weight Loss Clinic Salisbury Medications

The weight loss clinic Salisbury medications have well-characterised safety profiles established through extensive clinical trial programmes. GLP-1 receptor agonists most commonly cause gastrointestinal side effects including nausea (20-40% of patients), vomiting, diarrhoea, and constipation, typically mild-to-moderate and diminishing over 4-8 weeks [7]. Gradual dose escalation minimises these effects. Rare but serious risks include pancreatitis (0.1-0.2% incidence), gallbladder disease, and theoretical thyroid C-cell tumour risk based on rodent studies, though no causal link has been established in humans.

Orlistat-based treatments cause different side effects related to their mechanism, including oily spotting, faecal urgency, and flatulence with discharge, particularly when dietary fat intake exceeds recommendations. The weight loss clinic Salisbury clinical team provides comprehensive counselling on side effect management, warning signs requiring medical attention, and strategies to minimise adverse events. All prescription weight loss medications require ongoing monitoring, and patients should report persistent or severe symptoms to their prescriber. Superintendent pharmacist Tarun Kumar ensures every dispensing decision considers individual patient safety and appropriate clinical oversight.

Contraindications and Drug Interactions

The weight loss clinic Salisbury prescribing process screens for absolute contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe renal impairment (eGFR <30 mL/min/1.73m²). GLP-1 medications delay gastric emptying, potentially affecting absorption of oral medications including oral contraceptives, antibiotics, and levothyroxine, which may require timing adjustments. Patients taking insulin or sulfonylureas face increased hypoglycaemia risk and typically require dose reductions. Orlistat reduces absorption of fat-soluble vitamins (A, D, E, K) and some medications including ciclosporin and warfarin, necessitating monitoring and potential supplementation [8].

Why Choose Cured Pharmacy for Weight Loss Clinic Salisbury Services

Cured Pharmacy provides comprehensive weight loss clinic Salisbury services through our UK-registered online platform (GPhC 9012511), combining clinical expertise with competitive pricing and convenient home delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing activities, ensuring every prescription meets regulatory standards and patient safety requirements. We guarantee genuine UK-licensed medications sourced through authorised pharmaceutical wholesalers, never grey-market imports or unlicensed products.

The weight loss clinic Salisbury pricing at Cured Pharmacy represents the most competitive in the UK market, with transparent costs displayed before consultation and no hidden fees. Mounjaro starts from £124.99, Wegovy from £124.99, and Saxenda from £124.99, with new patient discount reducing initial costs by £124.99 using code Weightlossnew. Our clinical assessment takes under three minutes to complete, with most patients receiving prescriber approval within 24 hours. Discreet packaging ensures privacy, and our clinical team remains available for ongoing support throughout your weight loss journey. All prescription treatments are subject to clinical assessment and approval by a UK-registered prescriber.

Scientific References

1. Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., ... & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. [accessed 30 September 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 30 September 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 30 September 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. [accessed 30 September 2026]
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE guideline. [accessed 30 September 2026]
6. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 30 September 2026]
7. Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. [accessed 30 September 2026]
8. Medicines and Healthcare products Regulatory Agency. (2022). Orlistat: drug interactions and updated advice on fat-soluble vitamin supplementation. Drug Safety Update, 15(7). [accessed 30 September 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 30 September 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 30 September 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 30 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.